This page was exported from Dr Thomas Challenger
Export date: Sat Nov 18 15:32:01 2017 / +0000 GMT
Every so often a medical advance comes along that rewrites the script for treating a disease or condition. After today's announcements of impressive results of a new type of cholesterol-lowering drug, that scenario just might happen in the next few years.
The new drugs, called PCSK9 inhibitors, are monoclonal antibodies. They target and inactivate a specific protein in the liver. Knocking out this protein, called proprotein convertase subtilisin kexin 9, dramatically reduces the amount of harmful LDL cholesterol circulating in the bloodstream. Lower LDL translates into healthier arteries and fewer heart attacks, strokes, and other problems related to cholesterol-clogged arteries.
Post date: 2015-04-25 14:31:16
Post date GMT: 2015-04-25 04:31:16
Post modified date: 2016-04-20 13:09:59
Post modified date GMT: 2016-04-20 03:09:59
Powered by [ Universal Post Manager ] plugin. MS Word saving format developed by gVectors Team www.gVectors.com